PD-L1 IHC testing has a significant impact on patient eligibility for tailored specific immune oncology and require high diagnostic accuracy. This also underlines the need of appropriate EQA methods to evaluate the performance of PD-L1 IHC testing among the participating laboratories. At present, PD-L1 IHC testing is based on the “3D-approach” aligning Drug, Disease and read more…
Category Archives: News
IQN Path free access to CBQAReadout.ca
IQN Path is pleased to announce and endorse two new CBQAReadout modules including VENTANA PD-L1 (SP142) Assay, NSCLC, atezolizumab (3 hours) and VENTANA PD-L1 (SP263) Assay, NSCLC, nivolumab (3 hours). VENTANA PD-L1 (SP142) Assay, triple negative breast cancer, atezolizumab and nab-paclitaxel (2 hours) module will be open on June 1st, 2020. We will update you regularly read more…
SeraCare to Develop NGS Standards for Tumor Mutational Burden Monitoring
This article was originally published on http://www.clpmag.com/2019/04/seracare-develop-ngs-standards-tumor-mutational-burden-monitoring/ Under its agreement with IQN Path, SeraCare will develop, manufacture, and supply a range of highly characterized cell line genomic DNA and formalin-fixed, paraffin-embedded standards with confirmed low, mid, and high levels of mutational burden within their exome regions. Beginning in June 2019, the materials will be sent read more…
IQN Path Selects SeraCare Life Sciences for First-Ever Tumor Mutational Burden External Quality Assessment Program
International expert group focused on improving quality of clinical biomarker testing launching pilot TMB proficiency program in Spring 2019 MILFORD, Mass., WED. March 27, 2019 /PRNewswire/ — SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, announced today their successful selection as a technology partner read more…
New article in the journal BMC Cancer
IQN Path has an article from the liquid biopsy working group published in the journal BMC Cancer entitled: “International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA” The full article can be found here at this link: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4694-x
IQN Path’s Exhibition booth, ECP 2017 Amsterdam
This year IQN Path ASBL had it’s first exhibition booth at the 29th European Congress of Pathology, 2-5th September, 2017 https://www.esp-congress.org. As well as meeting with many IQN Path members, we also had the opportunity to speak with new potential members and also with laboratories looking to join EQA schemes. Many different projects and next read more…
New Publication: Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey
IQN Path is pleased to announce the first publication on Liquid Biopsy clinical implementation and quality assessment. Four EQA providers came together under the umbrella of IQN Path ASBL to run a pilot External Quality Assessment scheme for circulating free DNA. This publication “Review of the implementation of plasma ctDNA testing on behalf of IQN Path read more…
Quality in Pathology – IQN Path ASBL initiates a journal special issue
During the IQN Path Annual General Meeting in 2017, an idea was born to identify a channel for publications relating to quality issues in pathology, that would also provide a vehicle to collate papers and interesting articles related to External Quality Assessment in Pathology, amongst other topics that touch on quality. IQN Path ASBL reached read more…